What Is SLU-PP-332? Definition and What Research Reports
SLU-PP-332 is a synthetic small molecule that activates all three estrogen-related receptors (ERRα, ERRβ, ERRγ), nuclear receptors that help govern mitochondrial fuel use. It is not a peptide, despite often being listed alongside peptides. Published work is preclinical: researchers reported an exercise-like gene response and greater running capacity in mice, improvements in metabolic-syndrome, heart-failure and aging-kidney models, and the development of newer analogs. No human trial data appear in the cited literature.
Plain-language definition
SLU-PP-332 is a laboratory-made chemical that turns on a family of proteins inside cells called the estrogen-related receptors (ERRα, ERRβ and ERRγ). Those receptors act as master switches for how mitochondria — the energy-producing compartments of cells — build themselves and burn fuel. Because endurance exercise naturally recruits the same switches, animals treated with SLU-PP-332 in published experiments showed gene-expression and metabolic changes resembling parts of an aerobic exercise response, which is why science journalism has often labelled the molecule an "exercise mimetic" or "exercise in a pill." Everything published to date in the sources reviewed here is preclinical: cells, mice and rats. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any compound or health condition.
What SLU-PP-332 is in biochemical terms
In technical language, SLU-PP-332 is a synthetic pan-ERR agonist: a small organic molecule (not a peptide, protein, or hormone analog) that binds the ERR nuclear receptors and increases their transcriptional activity. ERRs are classed as "orphan" nuclear receptors because no natural circulating hormone has been established as their ligand; they instead depend heavily on coactivators such as PGC-1α to drive transcription of genes involved in fatty-acid oxidation, oxidative phosphorylation and mitochondrial biogenesis. The receptor biology predates the compound: a 2010 study characterised ERRγ as a key regulator of muscle mitochondrial activity and oxidative capacity (PMID 20418374), which helped establish why pharmacological ERR activation became a target of interest.
Why it is described as an "exercise mimetic"
The phrase traces to a 2023 report in which researchers described SLU-PP-332 as a synthetic ERRα/β/γ agonist that induced an acute aerobic exercise response in skeletal muscle and enhanced exercise capacity in mice, with the effect shown to be ERRα-dependent (PMID 36988910). The term is a description of a gene-program resemblance in rodents, not a claim that the molecule substitutes for training in people.
How the term is used — and where it is misused
SLU-PP-332 is frequently catalogued on the same lists as research peptides such as BPC-157 or tesamorelin. That grouping is a category error. Peptides are short chains of amino acids that usually act at cell-surface receptors; SLU-PP-332 is a small molecule that crosses the cell membrane and works on intracellular nuclear receptors. Common points of confusion include:
- "It's a peptide." It is not. The literature describes it as a synthetic agonist of nuclear receptors, not an amino-acid chain.
- "It's approved" or "clinically studied." The papers reviewed here are animal and cell studies. None of the cited reports describe human efficacy trials.
- "ERR" means "estrogen receptor." Estrogen-related receptors share sequence similarity with estrogen receptors but are a separate receptor family that does not bind estradiol as a classical activating ligand.
- Any ERR-targeting molecule is the same thing. Some compounds are ERR inverse agonists — the opposite pharmacology. DN200434, for example, was studied as an ERRγ-directed molecule that inhibited vascular smooth muscle cell proliferation and neointima formation in mice (PMID 36168774).
- Confusion with other metabolic nuclear-receptor drugs. Agents acting on entirely different receptors, such as an FXR/TGR5 dual agonist evaluated in diabetic and obese nephropathy models (PMID 29089371), are sometimes lumped in with ERR agonists because both appear in metabolic-disease literature.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the published literature reports
Exercise capacity and skeletal muscle
The foundational pharmacology paper reported that SLU-PP-332 activated ERRα, ERRβ and ERRγ, produced an acute aerobic exercise–type transcriptional response in skeletal muscle, and increased running capacity in mice; the study used ERRα-deficient animals to show the response depended on that receptor (PMID 36988910). A later pilot study examined ERR targeting as a strategy against age-related muscle atrophy associated with physical inactivity (PMID 40692696), extending the same receptor rationale to disuse models.
Metabolic syndrome
A 2024 pharmacology report titled A Synthetic ERR Agonist Alleviates Metabolic Syndrome described treatment of a mouse model with SLU-PP-332 and reported improvement in features of metabolic syndrome (PMID 37739806). Readers evaluating summaries of this work should note that the outcomes were rodent metabolic endpoints, not human clinical outcomes.
Heart failure
In a 2024 cardiovascular study, researchers reported that novel pan-ERR agonists ameliorated heart failure in animal models by enhancing cardiac fatty-acid metabolism and mitochondrial function (PMID 37961903). That paper is often cited as evidence that the chemical series, rather than SLU-PP-332 alone, is being optimised for organ-specific energetics.
Aging kidney
A 2023 pathology study reported that ERR agonism reversed markers of mitochondrial dysfunction and inflammation in the aging kidney (PMID 37717940). Related receptor-level work described an ESRRA (ERRα)–ATG5 mitophagy pathway that enhanced arginine metabolism and alleviated diabetic kidney disease in experimental models (PMID 41376268), illustrating why ERRα is studied in renal as well as muscle tissue.
Newer analogs
SLU-PP-332 is best understood as a tool compound rather than an endpoint. A 2026 report described SLU-PP-915 as an orally active estrogen receptor-related receptor agonist that enhanced aerobic exercise capacity (PMID 41421047), indicating continued medicinal-chemistry work on the scaffold.
Related terms
| Term | How it relates to SLU-PP-332 |
|---|---|
| ERRα / ESRRA | The receptor whose activity was required for the exercise-like response reported in mice (PMID 36988910). |
| ERRγ / ESRRG | An ERR isoform characterised as a regulator of muscle mitochondrial activity and oxidative capacity (PMID 20418374) and implicated in vascular calcification via BMP2 (PMID 26404484). |
| Pan-agonist | A molecule activating all three isoforms (α, β, γ), as described for the pan-ERR series in heart-failure models (PMID 37961903). |
| Inverse agonist | Opposite pharmacology at the same receptor family; exemplified by DN200434 (PMID 36168774). |
| Exercise mimetic | Informal label for compounds reproducing parts of an exercise transcriptional program; applied to SLU-PP-332 after the 2023 report (PMID 36988910). |
| ERRα screening | High-throughput work identified ERRα agonists within the Tox21 compound library, showing the receptor can be engaged by many unrelated chemicals (PMID 29216352). |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appSafety and adverse events: What Studies Report
The cited literature is preclinical, and none of these reports describe controlled human safety data for SLU-PP-332. Safety-relevant context in the receptor literature includes the observation that ERRγ activity was linked to vascular calcification through upregulation of BMP2 (PMID 26404484) and that a range of environmental and library chemicals can activate ERRα (PMID 29216352) — both reasons researchers have discussed isoform selectivity and off-target activation when evaluating pan-ERR pharmacology. Pharmacokinetic limitations were also a stated motivation for developing an orally active successor compound (PMID 41421047).
Regulatory status
SLU-PP-332 is not an approved medicine in the United States or the European Union and appears in commerce only as a research-use-only chemical. It is not a dietary-supplement ingredient and has no established human dosing framework in the literature reviewed here. Material labelled research-use-only is not manufactured or tested for human administration.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity (ACS Chemical Biology, 2023)
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome (Journal of Pharmacology and Experimental Therapeutics, 2024)
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney (American Journal of Pathology, 2023)
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function (Circulation, 2024)
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study (Frontiers in Physiology, 2025)
- An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (Journal of Pharmacology and Experimental Therapeutics, 2026)
- Estrogen-related receptor gamma is a key regulator of muscle mitochondrial activity and oxidative capacity (Journal of Biological Chemistry, 2010)
- ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease (Autophagy, 2026)
- DN200434 Inhibits Vascular Smooth Muscle Cell Proliferation and Prevents Neointima Formation in Mice after Carotid Artery Ligation (Endocrinology and Metabolism, 2022)
- Estrogen-Related Receptor γ Plays a Key Role in Vascular Calcification Through the Upregulation of BMP2 Expression (Arteriosclerosis, Thrombosis, and Vascular Biology, 2015)
- Identification of Estrogen-Related Receptor α Agonists in the Tox21 Compound Library (Endocrinology, 2018)
- FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity (Journal of the American Society of Nephrology, 2018)
Frequently asked questions
Is SLU-PP-332 a peptide?▾
No. It is a synthetic small molecule that activates the estrogen-related receptors, which are intracellular nuclear receptors, rather than a chain of amino acids acting at a cell-surface receptor. The defining pharmacology paper described it as a synthetic ERRα/β/γ agonist (PMID 36988910). It is grouped with peptides in online lists mainly by marketing convention, not by chemistry.
What does "pan-ERR agonist" mean?▾
It means the molecule activates all three estrogen-related receptor isoforms — ERRα, ERRβ and ERRγ — rather than one selectively. Researchers reported that pan-ERR agonists enhanced cardiac fatty-acid metabolism and mitochondrial function in heart-failure models (PMID 37961903), and that the exercise-related muscle response in mice depended specifically on ERRα (PMID 36988910).
Why is SLU-PP-332 called an exercise mimetic?▾
Because the 2023 study reported that it induced an acute aerobic exercise–type transcriptional response in mouse skeletal muscle and enhanced exercise capacity, with the effect requiring ERRα (PMID 36988910). The label describes a resemblance in gene programs measured in rodents. It is a descriptive research term, not a statement about outcomes in people.
Has SLU-PP-332 been tested in humans?▾
The literature summarised here is preclinical. Reports cover mouse and rat models of metabolic syndrome (PMID 37739806), heart failure (PMID 37961903), aging kidney (PMID 37717940) and inactivity-related muscle atrophy (PMID 40692696). None of these cited papers describe controlled human efficacy or safety trials, and the compound is not an approved medicine.
What is SLU-PP-915?▾
SLU-PP-915 is a later compound from the same ERR-agonist chemistry program. A 2026 report described it as an orally active estrogen receptor-related receptor agonist that enhanced aerobic exercise capacity in animal work (PMID 41421047). Its development reflects ongoing efforts to improve pharmacokinetic properties relative to earlier tool compounds in the series.
What safety information exists in the ERR literature?▾
No human safety datasets appear in the cited papers. Context includes reports that ERRγ activity contributed to vascular calcification via BMP2 upregulation (PMID 26404484) and that many unrelated library chemicals can activate ERRα (PMID 29216352), which is why isoform selectivity and off-target receptor activation are discussed by researchers studying pan-ERR pharmacology.
How does SLU-PP-332 differ from ERR inverse agonists?▾
Inverse agonists reduce receptor activity instead of increasing it. DN200434, an ERRγ-directed molecule, was reported to inhibit vascular smooth muscle cell proliferation and prevent neointima formation in mice after carotid artery ligation (PMID 36168774). Agonists such as SLU-PP-332 act in the opposite direction, increasing ERR transcriptional output (PMID 36988910).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.